Picture
Dr.Shruti Bhat, Star formulator and Ace leader within pharmaceutical R&D, a specialist with hiTech formulations and quality-by-design.  Shruti brings to you some highlights from current pharma and clinical research news, views and data. 

FDA Approves First-Ever Human Test Of Embryonic Stem Cell-Based Therapy.
The USFDA has approved "the world's first authorized test in people of a therapy derived from human embryonic stem cells." The clinical trial "could offer the first glimpse of the safety and possible effectiveness of a technology that has been hailed for its vast medical promise but also embroiled in political and ethical controversy." The trial ...

Scientists Create New Family Of "Super-Antibotics."
A new family of "'super-antibotics' capable of beating MRSA (Methicillin resistant Staph. aureus)  and other deadly infections” reports a study published in the journal ‘Nature’. In tests, one of the drugs killed strains of the hospital superbug resistant to antibiotics already in use. Others were ...

New Antibiotic Designed To Circumvent Drug Resistance.

GlaxoSmithKline Plc, the UK's biggest drugmaker, said it has come up with a new antibiotic designed to circumvent the drug resistance that makes many hospital-acquired infections difficult to treat." Glaxo's new compound "latches onto topoisomerase, which helps ...

Misoprostol May Revolutionize Abortion Around The World.
Researchers are finding an alternative" to abortions "that is safe, cheap, and very difficult for governments to restrict -- misoprostol." Misoprostol "pills are beginning to revolutionize abortion around ... 

More at ...http://www.pharm-education.com/2010/08/scientists-create-new-family-of-super.html 

Disclaimer- The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Http://www.drshrutibhat.comExpert at leading Pharmaceutical R&D.
Translates innovative concepts to PROFITS.
YouTube Channel : Http://www.youtube.com/user/ShrutiBhat10  
 


Comments




Leave a Reply